CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Rivaroxaban

Rivaroxaban

Last Updated: June 24, 2011

Result type: Reports

Project Number: SF0239-000

Product Line: Reimbursement Review

Generic Name: Rivaroxaban

Brand Name: Xarelto

Manufacturer: Bayer Inc.

Therapeutic Area: Venous thromboembolism, prevention

Indications: Thromboembolism (venous) prevention

Submission Type: Request For Advice

Project Status: Complete

Rivaroxaban

Files